REG-PanGenomic Health Inc: Admission to Trading on AQSE and First Day of Dealings

Pangenomic HealthAnnouncement

12/04/2023 07:15

12 April 2022

PanGenomic Health Inc.

(“PanGenomic” or the “Company”)

Admission to Trading on AQSE and First Day of Dealings

PanGenomic Health Inc. ("PanGenomic" or the "Company") (AQSE:NARA) (CSE:NARA),
a precision health company that has developed a self-care digital platform to
deliver personalised, evidence-based information about natural treatments to
support mental health, is pleased to announce that it has completed its
admission to the Access segment of the Aquis Stock Exchange ("AQSE") and
trading will commence at 8:00 a.m., 12 April GMT ("Admission") under the
ticker “NARA” and with its existing ISIN CA69842E2050. The Company's
shares will also continue to trade on the Canadian Securities Exchange
(“CSE”).

The Company has three digital health platforms:

i)             Nara App - a mental health mobile app which
provides consumers with a knowledge base tailored to an individual's unique
user profile, developed by tracking a user's treatment regimen and their
specific genomic, proteomics and microbiomic data.

ii)            Mindleap.com -  an app and telehealth platform for
holistic mental wellness which grants users access to great audio content and
blogs, a mental health tracker, and access to professional services for mental
well-being. Mindleap.com was acquired in November 2022 when the Company
purchased the entire issued share capital for Mindleap Health Inc from
Mydecine Innovations Group Inc.; and

iii)           Mujn Diagnostics - a digital therapeutics clinic
platform which provides health practitioners with access to a consumer's Nara
App data in order to assist them to optimize the identification of appropriate
natural remedies and monitor a patient's prognosis during treatment.

Robert Nygren, Executive Chair of PanGenomic, commented:

"The AQSE Growth Market listing presents PanGenomic Health with a tremendous
opportunity to reach UK-based investors interested in growth companies in the
digital health sector. Information about effective natural remedy solutions
for mental health conditions is in great demand, and our subscription-based
digital health platform has been designed to help individuals find trusted
information in a user-friendly manner."

The Company will have a dual listing with its common shares fully fungible
through a CREST Depositary Interest ("CDI").  The CDIs will carry the same
ISIN as the Common Shares listed in Canada on the CSE. The issued share
capital of PanGenomic comprises 99,128,169 Ordinary shares. Novum Securities
will act as the AQSE Corporate Advisor to PanGenomic going forward.

Sector Classification:

The Company will be classified as a Healthcare company on Access Segment of
the Aquis Stock Exchange.

This announcement, together with any documents incorporated by reference,
shall be deemed to constitute an admission document for the purposes of the
AQSE Growth Market Rules for Issuers – Access. It has not been approved or
reviewed by the Aquis Stock Exchange or the Financial Conduct Authority.

The Directors are of the opinion, having made due and careful enquiry, that
the working capital available to the Company is sufficient for a period of at
least twelve months following admission.

The Directors of PanGenomic take responsibility for this announcement.

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

For further information, please contact:

PanGenomic Health Inc.
Jerry Lai
Investor Relations, Canada
+1 778 743 4642
ir@pangenomic.com
Maryam Marissen
President & CEO
+1 778 743 4642
info@pangenomic.com
Website: https://www.pangenomic.com/

Novum Securities Limited, AQSE corporate Advisor
David Coffman / George Duxberry
Tel: +44 (0)207 399 9400

Yellow Jersey PR
Charles Goodwin / Shiv Thambirajah / Soraya Jackson
Investor Relations, UK
Tel: +44 (0)20 3004 9512

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care
digital platform to deliver personalized, evidence-based information about
natural treatments. The Company's initial focus is to support mental health.
Registered as a British Columbia benefit company, PanGenomic Health's mission
is to promote and improve the health and wellness of people and society by
providing a technology platform that identifies plant-based solutions tailored
to the health profile of each individual.

Directors

Vincent Lum

Mr. Lum has almost 20 years of experience in life science and medical device
company operations, along with investment and venture capital experience.
Vincent has served as CEO of Metaara Medical Diagnostics, CFO of Vidigami, CFO
of Hemex Health and CFO of CardioDigital (acquired by Medtronic). Vincent has
also served as VP and Venture Partner of MDS Capital and VP and Venture

partner of RBC Venture Capital and Manager of Investments at Advanced Systems
Institute. Vincent holds an MSc in Microbiology and Immunology and an MBA from
The University of British Columbia.

Robert Nygren

Mr. Nygren co-founded the psychedelics biotechnology company Havn Life
Sciences (CSE:HAVN) and is a founding director of Psy Integrated Health Corp,
which owns the Empower Health integrative health clinic in Vancouver. Robert
also co-founded the ETC3 Tech Centre in the South Research Campus of The
University of British Columbia, which provides facilities, funding and
advisory services for life science, agritech, cleantech and fintech companies.
Previously, Robert was CEO of Epic Data, a publicly-traded

software company, and CEO of Fincentric, a core-banking system sold to Open
Solutions (now Fiserv). Robert holds an LLB from Western University.

Peter Green

Mr. Green has leadership experience in both large corporations and small
businesses in the cloud technologies, AI, mobile and telecommunications
sectors. He has served as president of business solutions at Telus with
responsibility for its Telus Health division. Peter previously served as CEO
and a director of Mobilum Technologies Inc. (CSE: MBLM). Mr. Green is also a
director of Fobi AI Inc. (TSX.V: FOBI). Mr. Green received an Ordinary
National Diploma, Business Studies from Nelson and Colne College.

Jonathan Lutz

Mr. Lutz has experience in the video game industry, having served in various
executive management positions at Electronic Arts (EA) since 1998. He recently
had responsibility for Corporate Strategy, CTO Finance and Strategy,
Operations & Finance leadership for EA’s Strategic Growth Division. Jonathan
previously served as CFO of EA Canada. Mr. Lutz received an MA from Christ’s
College, Cambridge University and is an Associate of the Chartered Institute
of Management Accountants.

Senior Management

Maryam Marissen – Chief Executive officer

Ms. Marissen has over two decades of experience in consumer product marketing,
private clinic services and public advocacy.  She helped establish one of the
first online personal care and wellness e-commerce stores in North America. As
Managing Director of a Canadian government relations and public affairs
agency, she oversaw advocacy campaigns for healthcare, education, and public
policy. She has also been involved in psychedelic therapy research, consulting
with academic, industry, and regulatory stakeholders to develop clinical
pathways to patient care.

Kaidong Zhang – Chief Scientific Officer

Mr. Zhang has over 15 years of life science experience in academia and
industry. Recent R&D projects include clinical diagnosis development,
integrative medicine-based chronic disease management, nutraceutical product
development, and non-invasive diagnostic/therapeutic devices to manage chronic
prostate disease and non-alcoholic fatty liver diseases. Kaidong received a
postdoctoral training in protein engineering from the University of Rochester
and holds a PhD in Medicinal Chemistry and Organic Chemistry from the
University of Manitoba.

Colin Quon – Chief Technology Officer

Mr. Quon has managed complex technology projects and teams for nearly 30 years
in Canada. As founder of Excelar, he has overseen the development of health
data platforms for leading health authorities and academic institutions in
British Columbia. Colin also has significant experience developing
telecommunications platforms, during his product development and executive
roles at Nortel, Telos, EQO Communications, Global Relay and most recently as
founder of Chatnels Software. Colin holds an MBA from The University of
British Columbia and a BASc. in Electrical Engineering from Simon Fraser
University.

Tammy Gillis – Chief Financial Officer, Secretary and Treasurer

Ms. Gillis has over 20 years’ experience in the public markets bringing a
background in finance, reporting and regulatory requirements of manufacturing,
technology, and junior exploration industries. She obtained her CPA and CMA in
2008. Ms. Gillis previously served as CFO of New World Resource Corp.,
Northern Lion Gold Corp, Valorem Resources Inc., Nano One Materials Corp. and
Cava Healthcare Inc.

This news release includes certain statements that may be deemed
"forward-looking statements", including statements respecting the services to
be provided by PanGenomic and the consideration to be paid to PanGenomic. The
use of any of the words "anticipate", "continue", "estimate", "expect", "may",
"will", "would", "project", "should", "believe" and similar expressions are
intended to identify forward looking statements. Although PanGenomic believes
that the expectations and assumptions on which the forward-looking statements
are based are reasonable, undue reliance should not be placed on the
forward-looking statements because PanGenomic can give no assurance that they
will prove to be correct. Since forward-looking statements address future
events and conditions, by their very nature they involve inherent risks and
uncertainties. These statements speak only as of the date of this News
Release. Actual results could differ materially from those currently
anticipated due to a number of factors and risks including various risk
factors discussed in PanGenomic's disclosure documents which can be found
under PanGenomic's profile on www.sedar.com.



Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved